Heart of Hope: Poxel Unveils Promising New Weapon Against Devastating Cardiac Killer
- Breakthrough on the Horizon: Poxel (Euronext : POXEL - FR0012432516) is set to unveil compelling preclinical data for its novel compound, PXL065, in the fight against hypertrophic cardiomyopathy (HCM) at the prestigious European Society of Cardiology (ESC) Congress 2025.
- Targeting the Core Assault: PXL065, a unique deuterium-stabilized R-enantiomer of pioglitazone, shows remarkable promise by directly attacking the destructive mechanisms of HCM, including abnormal heart thickening, crippling fibrosis, and underlying metabolic chaos2, 3, 7.
- A Glimmer for a Genetic Scourge: Early victories in established preclinical models suggest PXL065 could become a crucial, disease-modifying therapy for HCM, a genetic condition that silently endangers 1 in 500 adults with the threat of sudden cardiac death2, 7.
LYON, France – A new dawn may be breaking for those battling hypertrophic cardiomyopathy (HCM), a relentless genetic heart disease. Poxel, a clinical-stage biopharmaceutical innovator, today announced that groundbreaking preclinical results for PXL065 will take center stage at the ESC Congress 2025 in Madrid, Spain, on September 1st.
HCM, a condition marked by thickened heart muscle, fibrosis, and a terrifying risk of sudden death, has long cast a shadow over affected families2. But PXL065, with its unique mechanism inhibiting the mitochondrial pyruvate carrier (MPC) and Acyl CoA Synthetase 4 (ACSL4), is showing profound potential to rewrite this narrative by tackling oxidative stress, inflammation, and fibrosis at their roots1, 3, 5.
In a pivotal preclinical study, funded by the German Center for Cardiovascular Research (DZHK) and conducted by leading HCM expert Prof. Dr. Cordula Wolf, PXL065 successfully prevented pathological heart remodeling, hypertrophy, and fibrosis in a validated HCM model7. This data strongly suggests PXL065 could offer more than just symptom management – it could modify the disease itself.
As Poxel prepares to share these significant findings with the world's leading cardiology experts, anticipation builds for a potential new era in treating not only HCM but also other serious metabolic disorders like MASH and ALD, where PXL065 is also under development2, 3, 5, 8. The journey from lab bench to life-changing therapy is arduous, but these results offer a powerful beacon of hope.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.